サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1401178

抗血小板薬市場- 世界の規模、シェア、動向分析、機会、予測レポート、2019～2029年

Antiplatelet Drugs Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Drugs ; By Indication ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region
出版日: | 発行: Blueweave Consulting | ページ情報: 英文 400 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗血小板薬市場- 世界の規模、シェア、動向分析、機会、予測レポート、2019～2029年
出版日: 2023年12月26日
発行: Blueweave Consulting
ページ情報: 英文 400 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

抗血小板薬の世界市場規模は2023～2029年にCAGR 5.32%で成長し、2029年には29億2,000万米ドルに達する

抗血小板薬の世界市場は、心血管疾患の有病率の増加、高齢化人口の増加、医薬品開発技術の進歩、予防医療に対する意識の高まり、血栓イベントの一次予防および二次予防を目的とした抗血小板薬に対する需要の急増などにより、活況を呈しています。

戦略コンサルティング・市場調査会社大手のBlueWeave Consultingは、最近の調査で、2022年の抗血小板薬の世界市場規模を21億4,000万米ドルと推定しました。2023年から2029年の予測期間中、抗血小板薬の世界市場規模はCAGR 5.32%で成長し、2029年には29億2,000万米ドルに達する見込みです。抗血小板薬の世界市場成長の背景には、世界の心血管疾患とそれに関連する問題の増加が大きな要因となっています。各患者の要求に応えるため、製薬会社はより洗練された個別化抗血小板薬の開発に注力しています。市場は研究開発活動の急速な増加を目の当たりにしており、その結果、新しい製剤が開発・上市される可能性があります。また、抗血小板薬は新興国でも使用頻度が高まっており、市場の拡大に拍車をかけています。また、患者のコンプライアンス向上や新しいドラッグデリバリー技術も、市場の拡大傾向に拍車をかけています。

機会- ヘルスケア・インフラへの投資の増加

世界のヘルスケア・インフラへの投資が大幅に増加する中、抗血小板薬の世界市場は投資家にとって有利な分野として浮上しています。医療施設の強化に注目が集まる中、先進的な抗血小板療法に対する需要が高まっています。この重要なヘルスケア分野に貢献し、心血管イベントの予防に重要な役割を果たす革新的な抗血小板薬へのアクセスを確保するチャンスをつかみましょう。この市場の急成長は、世界の保健衛生の優先事項に合致しているだけでなく、ヘルスケアの進歩が盛んになる中で持続可能なリターンを求める人々にとって、戦略的な投資手段を提供するものでもあります。

COVID-19が世界の抗血小板薬市場に与える影響

COVID-19の大流行は、世界中のヘルスケアシステムがウイルス対策に重点を移したため、世界の抗血小板薬市場に大きな影響を与えました。パンデミックのピーク時には、選択的治療が延期され、抗血小板薬の処方と需要が減少しました。また、サプライチェーンと製造の混乱により、一時的な供給不足と価格変動が生じた。しかし、遠隔医療や外来診療が重視されるようになり、患者が必要な医薬品を継続的に入手できるようになったことで、市場は回復力を示しました。パンデミックが沈静化するにつれ、抗血小板薬の世界市場は、日常的な医療サービスの再開と心血管の健康に対する意識の高まりによって回復すると予想されます。

抗血小板薬の世界市場-適応症別

適応症別に見ると、抗血小板薬の世界市場は心筋梗塞、経皮的冠動脈インターベンション、動脈血栓症に分けられます。心筋梗塞は抗血小板薬の世界市場において最大のセグメントです。このセグメントには心臓発作の治療が含まれ、これは世界的に重要な健康問題です。心筋梗塞患者の血液凝固を予防する抗血小板薬の需要は、心血管疾患の有病率の増加により依然として高いです。経皮的冠動脈インターベンションと動脈血栓症も重要なセグメントであるが、心筋梗塞は、この特定の病状における効果的かつ救命的な治療に対する重大な必要性によって、市場全体の収益と成長に最も大きく貢献しています。

当レポートの詳細な分析により、世界の抗血小板薬市場の成長可能性、今後の動向、統計に関する情報を提供します。また、総市場規模の予測を促進する要因にも焦点を当てています。当レポートは、世界の抗血小板薬市場の最新技術動向や、意思決定者が戦略的な意思決定を行う際に役立つ業界インサイトを提供することをお約束します。さらに、市場の成長促進要因・課題・競合についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の抗血小板薬市場に関する洞察

  • 業界のバリューチェーン分析
  • DROC分析
    • 成長促進要因
      • 心臓病および遺伝性疾患の有病率の増加
      • 高齢化に伴う新規経口抗凝固薬の需要の増大
    • 抑制要因
      • 厳格な規制政策
      • 抗血栓薬の高コストと副作用
    • 機会
      • 研究開発活動の増加
      • ヘルスケアインフラへの投資の増加
    • 課題
      • 新興経済諸国におけるヘルスケアインフラの不足
      • 一部の抗血小板薬の安全性、有効性、忍容性の限界
  • 技術の進歩/最近の開発
  • 規制の枠組み
  • ポーターのファイブフォース分析

第4章 世界の抗血小板薬市場概要

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
      • アスピリン
      • クロピドグレル
      • チカグレロル
      • プラスグレル
      • その他
    • 適応症別
      • 心筋梗塞
      • 経皮的冠動脈インターベンション
      • 動脈血栓症
      • その他
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
      • その他
    • 投与経路別
      • 経口
      • 注射
    • 最終用途別
      • 病院
      • 専門クリニック
      • ホームケア
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋（APAC）
      • ラテンアメリカ（LATAM）
      • 中東およびアフリカ（MEA）

第5章 北米の抗血小板薬市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
    • 適応症別
    • 流通チャネル別
    • 投与経路別
    • 最終用途別
    • 国別
      • 米国
      • カナダ

第6章 欧州の抗血小板薬市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
    • 適応症別
    • 流通チャネル別
    • 投与経路別
    • 最終用途別
    • 国別
      • ドイツ
      • 英国
      • イタリア
      • フランス
      • スペイン
      • ベルギー
      • ロシア
      • オランダ
      • その他

第7章 アジア太平洋地域の抗血小板薬市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
    • 適応症別
    • 流通チャネル別
    • 投与経路別
    • 最終用途別
    • 国別
      • 中国
      • インド
      • 日本
      • 韓国
      • オーストラリアとニュージーランド
      • インドネシア
      • マレーシア
      • シンガポール
      • ベトナム
      • その他

第8章 ラテンアメリカの抗血小板薬市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
    • 適応症別
    • 流通チャネル別
    • 投与経路別
    • 最終用途別
    • 国別
      • ブラジル
      • メキシコ
      • アルゼンチン
      • ペルー
      • その他

第9章 中東およびアフリカの抗血小板薬市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 薬剤別
    • 適応症別
    • 流通チャネル別
    • 投与経路別
    • 最終用途別
    • 国別
      • サウジアラビア
      • アラブ首長国連邦
      • カタール
      • クウェート
      • 南アフリカ
      • ナイジェリア
      • アルジェリア
      • その他

第10章 競合情勢

  • 主要企業とその製品のリスト
  • 世界の抗血小板薬企業の市場シェア分析、2022年
  • 経営パラメータによる競合ベンチマーキング
  • 主要な戦略的展開（合併、買収、パートナーシップなど）

第11章 世界の抗血小板薬市場に対する新型コロナウイルス感染症（COVID-19）の影響

第12章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望、 SWOT分析）

  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies（US）
  • Novartis AG
  • EnBiotix Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Ontores Biotechnologies Inc.
  • その他の主要企業

第13章 主な戦略的提言

第14章 調査手法

目次
Product Code: BWC231048

Global Antiplatelet Drugs Market Size Grows at CAGR of 5.32% During 2023-2029 to Reach USD 2.92 Billion by 2029

Global antiplatelet drugs market is flourishing due to the increasing prevalence of cardiovascular diseases, the growing aging population, advancements in drug development technologies, growing awareness about preventive healthcare, and a surge in demand for antiplatelet drugs for primary and secondary prevention of thrombotic events.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antiplatelet Drugs Market size at USD 2.14 billion in 2022. During the forecast period between 2023 and 2029, the Global Antiplatelet Drugs Market size is to grow at a CAGR of 5.32% reaching a value of USD 2.92 billion by 2029. An increase in cardiovascular illnesses and associated problems worldwide are major factors behind the growth of the global market for antiplatelet medicines. To meet the demands of each patient specifically, pharmaceutical companies are concentrating on creating more sophisticated and individualized antiplatelet medicines. The market is witnessing a rapid increase in R&D activities, which could result in the development and launch of novel drug formulations. Antiplatelet medications are also being used more frequently in emerging economies, which is fueling market expansion. Also, improvements in patient compliance and new drug delivery techniques are adding to the market's upward trend.

Opportunity - Increasing Investments in Healthcare Infrastructure

As worldwide healthcare infrastructure experiences a significant upswing in investments, the Global Antiplatelet Drugs Market emerges as a lucrative sector for prospective investors. With a rising focus on enhancing medical facilities, there is a growing demand for advanced antiplatelet therapies. Seize the opportunity to contribute to this vital healthcare segment, ensuring access to innovative antiplatelet drugs that play a crucial role in preventing cardiovascular events. This market surge not only aligns with global health priorities but also presents a strategic investment avenue for those seeking sustainable returns in the flourishing landscape of healthcare advancements.

Impact of COVID-19 on Global Antiplatelet Drugs Market

The COVID-19 pandemic significantly impacted Global Antiplatelet Drugs Market, as healthcare systems worldwide shifted focus to combat the virus. During the peak of the pandemic, elective procedures were postponed, leading to reduced prescriptions and demand for antiplatelet drugs. Also, disruptions in the supply chain and manufacturing caused temporary shortages and price fluctuations. However, the market showed resilience with the increasing emphasis on telemedicine and outpatient care, ensuring continuous patient access to essential medications. As the pandemic abates, the Global Antiplatelet Drugs Market is expected to rebound, driven by the resumption of routine medical services and growing awareness of cardiovascular health.

Global Antiplatelet Drugs Market - By Indication

By indication, Global Antiplatelet Drugs Market is divided into Myocardial infarction, Percutaneous Coronary Interventions, and Arterial Thrombosis segments. Myocardial infarction is the largest segment in the Global Antiplatelet Drugs Market. The segment encompasses the treatment of heart attacks, which is a significant health concern worldwide. The demand for antiplatelet drugs to prevent blood clotting in patients suffering from myocardial infarction remains high due to the increasing prevalence of cardiovascular diseases. While percutaneous coronary interventions and arterial thrombosis are also important segments, myocardial infarction stands out as the most substantial contributor to the overall market revenue and growth, driven by the critical need for effective and life-saving treatments in this specific medical condition.

Competitive Landscape

Global Antiplatelet Drugs Market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Antiplatelet Drugs Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antiplatelet Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antiplatelet Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Drugs Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antiplatelet Drugs Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increase in the prevalence of cardiac and hereditary diseases
      • 3.2.1.2. Growing demand for novel oral anticoagulants coupled with the aging population
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulatory policies
      • 3.2.2.2. High cost and side effects of antithrombotic drugs
    • 3.2.3. Opportunities
      • 3.2.3.1. Increase in the number of research and development activities
      • 3.2.3.2. Increasing investment in healthcare infrastructure
    • 3.2.4. Challenges
      • 3.2.4.1. Lack of healthcare infrastructure in developing economies
      • 3.2.4.2. Limitations in safety, efficacy, and tolerability of some antiplatelet drugs
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antiplatelet Drugs Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drugs
      • 4.2.1.1. Aspirin
      • 4.2.1.2. Clopidogrel
      • 4.2.1.3. Ticagrelor
      • 4.2.1.4. Prasugrel
      • 4.2.1.5. Others
    • 4.2.2. By Indication
      • 4.2.2.1. Myocardial Infraction
      • 4.2.2.2. Percutaneous Coronary Interventions
      • 4.2.2.3. Arterial Thrombosis
      • 4.2.2.4. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacy
      • 4.2.3.2. Retail Pharmacy
      • 4.2.3.3. Online Pharmacy
      • 4.2.3.4. Others
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
    • 4.2.5. By End Use
      • 4.2.5.1. Hospitals
      • 4.2.5.2. Specialty Clinics
      • 4.2.5.3. Homecare
      • 4.2.5.4. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Antiplatelet Drugs Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs
    • 5.2.2. By Indication
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Route of Administration
    • 5.2.5. By End Use
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By Drugs
      • 5.2.6.1.2. By Indication
      • 5.2.6.1.3. By Distribution Channel
      • 5.2.6.1.4. By Route of Administration
      • 5.2.6.1.5. By End Use
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By Drugs
      • 5.2.6.2.2. By Indication
      • 5.2.6.2.3. By Distribution Channel
      • 5.2.6.2.4. By Route of Administration
      • 5.2.6.2.5. By End Use

6. Europe Antiplatelet Drugs Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Use
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By Drugs
      • 6.2.6.1.2. By Indication
      • 6.2.6.1.3. By Distribution Channel
      • 6.2.6.1.4. By Route of Administration
      • 6.2.6.1.5. By End Use
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By Drugs
      • 6.2.6.2.2. By Indication
      • 6.2.6.2.3. By Distribution Channel
      • 6.2.6.2.4. By Route of Administration
      • 6.2.6.2.5. By End Use
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By Drugs
      • 6.2.6.3.2. By Indication
      • 6.2.6.3.3. By Distribution Channel
      • 6.2.6.3.4. By Route of Administration
      • 6.2.6.3.5. By End Use
      • 6.2.6.4. France
      • 6.2.6.4.1. By Drugs
      • 6.2.6.4.2. By Indication
      • 6.2.6.4.3. By Distribution Channel
      • 6.2.6.4.4. By Route of Administration
      • 6.2.6.4.5. By End Use
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By Drugs
      • 6.2.6.5.2. By Indication
      • 6.2.6.5.3. By Distribution Channel
      • 6.2.6.5.4. By Route of Administration
      • 6.2.6.5.5. By End Use
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By Drugs
      • 6.2.6.6.2. By Indication
      • 6.2.6.6.3. By Distribution Channel
      • 6.2.6.6.4. By Route of Administration
      • 6.2.6.6.5. By End Use
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By Drugs
      • 6.2.6.7.2. By Indication
      • 6.2.6.7.3. By Distribution Channel
      • 6.2.6.7.4. By Route of Administration
      • 6.2.6.7.5. By End Use
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By Drugs
      • 6.2.6.8.2. By Indication
      • 6.2.6.8.3. By Distribution Channel
      • 6.2.6.8.4. By Route of Administration
      • 6.2.6.8.5. By End Use
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By Drugs
      • 6.2.6.9.2. By Indication
      • 6.2.6.9.3. By Distribution Channel
      • 6.2.6.9.4. By Route of Administration
      • 6.2.6.9.5. By End Use

7. Asia Pacific Antiplatelet Drugs Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Use
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By Drugs
      • 7.2.6.1.2. By Indication
      • 7.2.6.1.3. By Distribution Channel
      • 7.2.6.1.4. By Route of Administration
      • 7.2.6.1.5. By End Use
      • 7.2.6.2. India
      • 7.2.6.2.1. By Drugs
      • 7.2.6.2.2. By Indication
      • 7.2.6.2.3. By Distribution Channel
      • 7.2.6.2.4. By Route of Administration
      • 7.2.6.2.5. By End Use
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By Drugs
      • 7.2.6.3.2. By Indication
      • 7.2.6.3.3. By Distribution Channel
      • 7.2.6.3.4. By Route of Administration
      • 7.2.6.3.5. By End Use
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By Drugs
      • 7.2.6.4.2. By Indication
      • 7.2.6.4.3. By Distribution Channel
      • 7.2.6.4.4. By Route of Administration
      • 7.2.6.4.5. By End Use
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By Drugs
      • 7.2.6.5.2. By Indication
      • 7.2.6.5.3. By Distribution Channel
      • 7.2.6.5.4. By Route of Administration
      • 7.2.6.5.5. By End Use
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By Drugs
      • 7.2.6.6.2. By Indication
      • 7.2.6.6.3. By Distribution Channel
      • 7.2.6.6.4. By Route of Administration
      • 7.2.6.6.5. By End Use
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By Drugs
      • 7.2.6.7.2. By Indication
      • 7.2.6.7.3. By Distribution Channel
      • 7.2.6.7.4. By Route of Administration
      • 7.2.6.7.5. By End Use
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By Drugs
      • 7.2.6.8.2. By Indication
      • 7.2.6.8.3. By Distribution Channel
      • 7.2.6.8.4. By Route of Administration
      • 7.2.6.8.5. By End Use
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By Drugs
      • 7.2.6.9.2. By Indication
      • 7.2.6.9.3. By Distribution Channel
      • 7.2.6.9.4. By Route of Administration
      • 7.2.6.9.5. By End Use
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By Drugs
      • 7.2.6.10.2. By Indication
      • 7.2.6.10.3. By Distribution Channel
      • 7.2.6.10.4. By Route of Administration
      • 7.2.6.10.5. By End Use

8. Latin America Antiplatelet Drugs Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Use
    • 8.2.6. By Country
      • 8.2.6.1. Brazil
      • 8.2.6.1.1. By Drugs
      • 8.2.6.1.2. By Indication
      • 8.2.6.1.3. By Distribution Channel
      • 8.2.6.1.4. By Route of Administration
      • 8.2.6.1.5. By End Use
      • 8.2.6.2. Mexico
      • 8.2.6.2.1. By Drugs
      • 8.2.6.2.2. By Indication
      • 8.2.6.2.3. By Distribution Channel
      • 8.2.6.2.4. By Route of Administration
      • 8.2.6.2.5. By End Use
      • 8.2.6.3. Argentina
      • 8.2.6.3.1. By Drugs
      • 8.2.6.3.2. By Indication
      • 8.2.6.3.3. By Distribution Channel
      • 8.2.6.3.4. By Route of Administration
      • 8.2.6.3.5. By End Use
      • 8.2.6.4. Peru
      • 8.2.6.4.1. By Drugs
      • 8.2.6.4.2. By Indication
      • 8.2.6.4.3. By Distribution Channel
      • 8.2.6.4.4. By Route of Administration
      • 8.2.6.4.5. By End Use
      • 8.2.6.5. Rest of LATAM
      • 8.2.6.5.1. By Drugs
      • 8.2.6.5.2. By Indication
      • 8.2.6.5.3. By Distribution Channel
      • 8.2.6.5.4. By Route of Administration
      • 8.2.6.5.5. By End Use

9. Middle East and Africa Antiplatelet Drugs Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Use
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By Drugs
      • 9.2.6.1.2. By Indication
      • 9.2.6.1.3. By Distribution Channel
      • 9.2.6.1.4. By Route of Administration
      • 9.2.6.1.5. By End Use
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By Drugs
      • 9.2.6.2.2. By Indication
      • 9.2.6.2.3. By Distribution Channel
      • 9.2.6.2.4. By Route of Administration
      • 9.2.6.2.5. By End Use
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By Drugs
      • 9.2.6.3.2. By Indication
      • 9.2.6.3.3. By Distribution Channel
      • 9.2.6.3.4. By Route of Administration
      • 9.2.6.3.5. By End Use
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By Drugs
      • 9.2.6.4.2. By Indication
      • 9.2.6.4.3. By Distribution Channel
      • 9.2.6.4.4. By Route of Administration
      • 9.2.6.4.5. By End Use
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By Drugs
      • 9.2.6.5.2. By Indication
      • 9.2.6.5.3. By Distribution Channel
      • 9.2.6.5.4. By Route of Administration
      • 9.2.6.5.5. By End Use
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By Drugs
      • 9.2.6.6.2. By Indication
      • 9.2.6.6.3. By Distribution Channel
      • 9.2.6.6.4. By Route of Administration
      • 9.2.6.6.5. By End Use
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By Drugs
      • 9.2.6.7.2. By Indication
      • 9.2.6.7.3. By Distribution Channel
      • 9.2.6.7.4. By Route of Administration
      • 9.2.6.7.5. By End Use
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By Drugs
      • 9.2.6.8.2. By Indication
      • 9.2.6.8.3. By Distribution Channel
      • 9.2.6.8.4. By Route of Administration
      • 9.2.6.8.5. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antiplatelet Drugs Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antiplatelet Drugs Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Eli Lilly and Company
  • 12.2. Pfizer Inc.
  • 12.3. GSK Group of Companies (U.S)
  • 12.4. Novartis AG
  • 12.5. EnBiotix Inc.
  • 12.6. Johnson & Johnson Private Limited
  • 12.7. Merck & Co., Inc.
  • 12.8. Alexion Pharmaceuticals, Inc.
  • 12.9. Melinta Therapeutics, LLC
  • 12.10. Vertex Pharmaceuticals Incorporated
  • 12.11. AnaSpec
  • 12.12. AMP Biotech
  • 12.13. Phoenix Biotechnology Inc.
  • 12.14. Novabiotics
  • 12.15. Ontores Biotechnologies Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations